Fig. 2: Progression-free survival. | Blood Cancer Journal

Fig. 2: Progression-free survival.

From: KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

Fig. 2

A shows a Kaplan–Meier curve of progression-free survival across all target doses and B shows a Kaplan–Meier curve of progression-free survival at the target dose of 450 × 106 CAR + T cells based on Independent Response Committee Review according to IMWG criteria applying Food and Drug Administration censoring rules. IMWG denotes International Myeloma Working Group, NE not estimable.

Back to article page